GlassScriptPhysician profile
Ivy A Lee
NPI 1699947317
$3,531.69
in general payments reported to CMS, 2019-2025
14 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $251 · 2021: $579 · 2022: $50.92 · 2023: $55.92 · 2024: $2,032 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,004 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,004.00 |
| Food and Beverage | $484.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,095.44 | 2021-2025 | |
| Abbvie INC. | $706.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $128.60 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $115.26 | 2020-2021 | |
| Ucb, INC. | $90.12 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $74.48 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $70.65 | 2021 | |
| Revance Therapeutics, INC. | $67.84 | 2025 | Daxxify |
| Incyte Corporation | $51.84 | 2024-2025 | Opzelura |
| Biofrontera INC. | $49.85 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $26.53 | 2020 | |
| Mayne Pharma Commercial LLC | $24.40 | 2019 | |
| Kyowa Kirin, INC. | $17.37 | 2025 | |
| Celgene Corporation | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.